Drug · CHEMBL433
VALPROATE SODIUM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. VALPROATE SODIUM. Drugs and targets, record CHEMBL433. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL433
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Delepsine, Depacon, Depakine, Epilim, Epilim 200, Epilim 500, Epilim chrono 200, Epilim chrono 300, Epilim chrono 500, Epilim chronosphere, Epilim iv, Episenta, Kentilim, Orfiril, Orlept
- ChEMBL
- Other names
A-44090, ABBOTT 44090, ABBOTT-44090, KW-6066N, NSC-732626, NSC-757376, Natrii valproas, Selenica, Sodium 2-propylpentanoate, Sodium valproate, Valproic acid sodium salt (1:1), Valproic acid, sodium, Valproic acid, sodium salt
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | Succinate semialdehyde dehydrogenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/7915 |
Source ChEMBL
Diseases13
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 13Source Open Targets
See all 13 diseasesTrials26
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04698525 | Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. | Phase 3 | 33 | 2023-05-17 | valproate sodium | Its name | ClinicalTrials.gov |
| NCT03616223 | FX-322 in Sensorineural Hearing Loss | Phase 1/2 | 23 | 2022-11-14 | sodium valproate | Its name | ClinicalTrials.gov |
| NCT06081283 | Antiseizure Medication in Seizure Networks at Early Acute Brain Injury | Phase 4 | 5 | 2025-11-14 | valproate sodium | Its name | ClinicalTrials.gov |
| NCT00004817 | Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures | Phase 3 | 385 | valproate sodium | Its name | ClinicalTrials.gov | |
| NCT00264173 | VALID : VAlproate Versus LIthium in Bipolar Disorders | Phase 4 | 270 | valproate sodium | Its name | ClinicalTrials.gov | |
| NCT03652974 | Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy | Phase 4 | 145 | sodium valproate | Its name | ClinicalTrials.gov | |
| NCT04997811 | Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes | Phase 2 | 120 | sodium valproate | Its name | ClinicalTrials.gov | |
| NCT02011750 | Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia | Phase 4 | 109 | sodium valproate | Its name | ClinicalTrials.gov | |
| NCT00000439 | Drug Treatment for Alcoholics With Bipolar Disorder | Phase 2 | 72 | sodium valproate | Its name | ClinicalTrials.gov | |
| NCT05017454 | Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids | Early phase 1 | 67 | sodium valproate | Its name | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Valproate Group vs Memantine: deaths from any cause | 0 of 17 | 0 of 16 | 33 | NCT04698525 | Trial comparisons |
| Valproate Group vs Memantine: serious adverse events | 2 of 17 | 1 of 16 | 33 | NCT04698525 | Trial comparisons |
| Seizure Network Positive Subjects vs Seizure Network Negative Subjects: Dropout Rate | 2 of 3 | 2 of 2 | 5 | NCT06081283 | Trial comparisons |
| Seizure Network Positive Subjects vs Seizure Network Negative Subjects: deaths from any cause | 1 of 3 | 2 of 2 | 5 | NCT06081283 | Trial comparisons |
Papers from its trials20
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Task Switching Test | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL433
GET https://conductscience.org/api/drugs/v1/CHEMBL433/trials?page=2